GERM ETFMG Treatments Testing and Advancements ETF

72

NYSE ARCA | ETF

Price
$18.2854
Increased by +0.79%
Dollar Volume (20D)
31.3 K
ADR%
0.93
Healthcare - 100.00%Basic Materials - 0.00%Communication Services - 0.00%Consumer Cyclicals - 0.00%Consumer Defensive - 0.00%Energy - 0.00%Financial Services - 0.00%Industrials - 0.00%Real Estate - 0.00%Technology - 0.00%Utilities - 0.00%
Healthcare - 100.00%
Basic Materials - 0.00%
Communication Services - 0.00%
Consumer Cyclicals - 0.00%
Consumer Defensive - 0.00%
Energy - 0.00%
Financial Services - 0.00%
Industrials - 0.00%
Real Estate - 0.00%
Technology - 0.00%
Utilities - 0.00%

Top 20 Holdings

Asset Name Sector Industry Weight
NK NantKwest Inc Healthcare Biotechnology 7.94%
MRNA Moderna Inc Healthcare Biotechnology 7.58%
DGX Quest Diagnostics Incorporated Healthcare Diagnostics & Research 7%
BNTX BioNTech SE Healthcare Biotechnology 6.19%
ALNY Alnylam Pharmaceuticals Inc Healthcare Biotechnology 6.11%
LH Laboratory Corporation of America Holdings Healthcare Diagnostics & Research 5.92%
DVAX Dynavax Technologies Corporation Healthcare Drug Manufacturers - Specialty & Generic 3.64%
IMCR Immunocore Holdings Ltd Healthcare Biotechnology 3.61%
QL1A QUIDELORTHO DL-001 Healthcare Medical Devices 3.6%
BIO Bio-Rad Laboratories Inc Healthcare Medical Devices 3.55%
PCVX Vaxcyte Inc Healthcare Biotechnology 3.45%
ZLAB Zai Lab Ltd Healthcare Biotechnology 3.21%
ABCL Abcellera Biologics Inc Healthcare Biotechnology 2.99%
VIR Vir Biotechnology Inc Healthcare Biotechnology 2.77%
OPK Opko Health Inc Healthcare Diagnostics & Research 2.35%
BCRX BioCryst Pharmaceuticals Inc Healthcare Biotechnology 2.16%
ARCT Arcturus Therapeutics Holdings Inc Healthcare Biotechnology 1.75%
ICVX Icosavax Inc Healthcare Biotechnology 1.66%
HLVX Hillevax Inc Healthcare Biotechnology 1.58%
SIGA SIGA Technologies Inc Healthcare Drug Manufacturers - Specialty & Generic 1.54%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Under normal circumstances, the fund invests at least 80% of its net assets in U.S.-listed equity securities or ADRs of Treatments, Testing and Advancements Companies. In general, the index seeks to be comprised of companies performing advancements in research, development, and commercialization of treatments or vaccines for infectious diseases, or engaged in the advancement of research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified.